BATON ROUGE, La., Jan. 28, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, is pleased to announce the appointment of Mitesh J. Borad, M.D. to the Company’s Scientific Advisory Board, effective immediately.
Dr. Borad is currently an Associate Professor of Medicine at Mayo Clinic College of Medicine and Science. He also serves as the Director of the GI Cancer Cellular, Gene and Virus Therapy lab, Director of the Liver and Biliary Cancer Research Program and Deputy Director, Biomarker Discovery Program at the Center for Individualized Medicine at Mayo Clinic. Dr. Borad concurrently serves on the National Cancer Institute’s Hepatobiliary Task Force, an appointment he has held since 2011. Prior to joining Mayo Clinic, he spent three years as a Drug Development Scholar/Genomics Medicine Scholar at the Translational Genomic Research Institute, where he worked closely with world-renowned experts, including Dr. Daniel D. Von Hoff.
He earned his B.S. in Biomedical Engineering (summa cum laude) from Boston University and his M.D. from the University of Medicine and Dentistry of New Jersey. Subsequently, Dr. Borad obtained his internal medical training at Cedars-Sinai Medical Center and completed his Medical Oncology Fellowship at Tulane University School of Medicine.
Dr. Borad holds a Certification in Medical Oncology from the American Board of Internal Medicine and is a member of more than 20 professional organizations and committees, including presently being seated as Vice Chairman of the International Cholangiocarcinoma Research Network. Dr. Borad has a long and distinguished list of accolades and accomplishments, such as earning a 2014 New Innovator Award from the National Institute of Health and being named 2011 Paul Calabresi Scholar in Clinical-Translational Research by Mayo Clinic.
“Dr. Borad is a highly accomplished oncologist with specialties and interests that align with our pipeline development plans, in particular our targeted chemotherapy technology,” commented Dr. Brian Barnett, Chief Executive Officer at OncBioMune. “I have no doubt that his expertise in drug development and precision medicines will prove invaluable as a scientific advisor as we explore new ways to benefit cancer patients and evaluate the potential of our technology for pancreatic, liver and biliary cancers.”
Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.
About OncBioMune Pharmaceuticals, Inc.
OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, based on their proprietary therapeutic cancer vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. Our lead pipeline product, ProscaVax™, has successfully completed enrollment and vaccination of the prostate cancer patients and is collecting long-term follow-up results for the 1a portion of their Phase 1a/1b clinical trial. Due to the impressive results and proven safety profile of ProscaVax™, OncBioMune is forgoing the 1b portion of the trial to advance ProscaVax™ into Phase 2 clinical trials A Phase 2 clinical trial is scheduled to commence at Beth Israel Deaconess Medical Center a Harvard University teaching hospital evaluating ProscaVax as a front-line therapy in prostate cancer patients in the “active surveillance” category, representing the first mid-stage trial of an immunotherapeutic vaccine in this patient population. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
OncBioMune Pharmaceuticals, Inc.
Brian Barnett, MD
Chief Executive Officer